MCID: FLR002
MIFTS: 55

Filariasis

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Filariasis

MalaCards integrated aliases for Filariasis:

Name: Filariasis 12 74 58 54 43 15 71 32
Disease Due to Superfamily Filarioidea 12

Characteristics:

Orphanet epidemiological data:

58
filariasis
Inheritance: Not applicable; Prevalence: >1/1000; Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:1080
ICD9CM 34 125.9
MeSH 43 D005368
NCIt 49 C34611
SNOMED-CT 67 50342004
MESH via Orphanet 44 D005368
ICD10 via Orphanet 33 B74.0 B74.1 B74.2 more
UMLS via Orphanet 72 C0016085
Orphanet 58 ORPHA2034
UMLS 71 C0016085

Summaries for Filariasis

Disease Ontology : 12 A parasitic helminthiasis infectious disease that involves parasitic infection of the lymphatics and subcutaneous tissue by nematodes of the superfamily Filarioidea.

MalaCards based summary : Filariasis, also known as disease due to superfamily filarioidea, is related to filarial elephantiasis and elephantiasis. An important gene associated with Filariasis is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Diethylcarbamazine and Doxycycline have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and breast, and related phenotypes are immune system and hematopoietic system

Wikipedia : 74 Filariasis is a parasitic disease caused by an infection with roundworms of the Filarioidea type. These... more...

Related Diseases for Filariasis

Diseases related to Filariasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 710)
# Related Disease Score Top Affiliating Genes
1 filarial elephantiasis 34.8 TLR4 TLR2 IL5 IL10
2 elephantiasis 33.7 IL5 IL10 FLT4
3 onchocerciasis 32.6 LGALS3BP IL5 IL2 IGHE CCL5
4 lymphadenitis 31.2 TNF TLR4 IL10 IFNG
5 hypereosinophilic syndrome 31.2 IL5 IL2 IL10 IGHE IFNG CCL5
6 ascaris lumbricoides infection 31.1 IL6 IL5 IFNG
7 endomyocardial fibrosis 31.0 TNF IL5 IL10
8 orchitis 31.0 TNF IL6 IL2 IL10
9 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.9 IL10 IFNG CTLA4
10 encephalitis 30.9 TNF IL6 IL10 CCL5
11 yellow fever 30.8 IL6 IL5 CCL5
12 dengue disease 30.8 TNF CCL5 ALB
13 strongyloidiasis 30.7 LGALS3BP IL5 IGHE IFNG
14 trachoma 30.6 TNF IL6 IL10
15 cellulitis 30.6 TNF IL6 IL5 IL10 FLT4
16 lymphangiosarcoma 30.6 TNF FLT4
17 chikungunya 30.6 TNF IL6 CCL5
18 poliomyelitis 30.6 TNF IL10 IFNG
19 severe combined immunodeficiency 30.5 IL6 IL5 IL2 IL10 IFNG
20 taeniasis 30.4 TLR4 IL10 ALB
21 b cell deficiency 30.4 IL2 IL10 CTLA4
22 trichomoniasis 30.4 TNF IL6 IL2
23 ige responsiveness, atopic 30.4 IL5 IL10 IGHE IFNG
24 urinary schistosomiasis 30.4 IL5 IGHE IFNG CTLA4
25 panuveitis 30.4 TNF IL6 IL10
26 urticaria 30.4 TNF IL6 IL5 IGHE
27 pericarditis 30.3 TNF IL6 IFNG ALB
28 fascioliasis 30.3 IL10 IFNG ALB
29 amebiasis 30.3 TNF TLR4 TLR2 ALB
30 rheumatic heart disease 30.3 TNF TLR2 IL6 IL10
31 mastitis 30.3 TLR2 IL6 CCL5 ALB
32 protein-energy malnutrition 30.3 TNF IL6 ALB
33 cysticercosis 30.2 TLR4 PDCD1LG2 IL6 IL10 IGHE
34 schistosomiasis 30.2 TNF IL5 IL2 IL10 IGHE IFNG
35 typhoid fever 30.2 TNF TLR4 IL6 IFNG ALB
36 pleurisy 30.1 TNF TLR4 TLR2 IL2 IFNG
37 lepromatous leprosy 30.1 TNF TLR2 IL2 IL10 IFNG
38 bacterial infectious disease 30.1 TNF TLR9 TLR4 TLR2 TLR1 IL6
39 endocarditis 30.1 TNF TLR6 TLR2 IL6 IL10 IFNG
40 uveitis 30.1 TNF IL6 IL2 IL10 IFNG CTLA4
41 parasitic helminthiasis infectious disease 30.1 TNF TLR9 TLR4 TLR2 IL6 IL5
42 mucocutaneous leishmaniasis 30.1 TNF TLR9 IL2 IL10 IFNG
43 posterior uveitis 30.0 TNF IL6 IL5 IL2 IFNG
44 lichen planus 30.0 TNF IL6 IL2 IL10 IFNG
45 plasmodium falciparum malaria 30.0 TNF IL6 IL10 IFNG CHIT1
46 varicose veins 30.0 TNF LGALS3BP IL6 FOXC2
47 gastritis 30.0 TNF TLR4 IL6 IL10 CCL5
48 keratitis, hereditary 29.9 TNF TLR9 TLR4 TLR2 IL6 IL10
49 dengue hemorrhagic fever 29.9 TNF IL6 IL10 IFNG ALB
50 meningoencephalitis 29.9 TNF IL6 IL10 CCL5 ALB

Graphical network of the top 20 diseases related to Filariasis:



Diseases related to Filariasis

Symptoms & Phenotypes for Filariasis

MGI Mouse Phenotypes related to Filariasis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.35 ALB CCL5 CHIT1 CTLA4 FLT4 FOXC2
2 hematopoietic system MP:0005397 10.28 CCL5 CTLA4 IFNG IL10 IL2 IL5
3 homeostasis/metabolism MP:0005376 10.28 ALB CTLA4 FLT4 FOXC2 IFNG IL10
4 digestive/alimentary MP:0005381 10.27 ALB CTLA4 FLT4 FOXC2 IFNG IL10
5 cardiovascular system MP:0005385 10.22 ALB CTLA4 FLT4 FOXC2 IFNG IL10
6 liver/biliary system MP:0005370 10.1 ALB CTLA4 FLT4 FOXC2 IFNG IL10
7 muscle MP:0005369 9.91 ALB FLT4 FOXC2 IFNG IL10 IL6
8 neoplasm MP:0002006 9.85 ALB IFNG IL10 IL2 IL5 IL6
9 no phenotypic analysis MP:0003012 9.5 FLT4 FOXC2 IFNG IL10 IL2 PDCD1LG2
10 respiratory system MP:0005388 9.32 CTLA4 FOXC2 IFNG IL10 IL2 IL5

Drugs & Therapeutics for Filariasis

Drugs for Filariasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 4 90-89-1 3052
2
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
3 Anti-Bacterial Agents Phase 4
4 Antimalarials Phase 4
5 Vitamins Phase 3
6 Reslizumab Approved, Investigational Phase 2
7
Piperaquine Experimental, Investigational Phase 2 4085-31-8 5079497
8
Dihydroartemisinin Experimental, Investigational Phase 2 71939-50-9 6918483
9 Artemisinins Phase 2
10 Artemisinine Phase 2
11 Antibodies, Monoclonal Phase 2
12 Respiratory System Agents Phase 2
13 Anti-Asthmatic Agents Phase 2
14 Immunoglobulins Phase 2
15 Antibodies Phase 2
16 Imatinib Mesylate Phase 2 220127-57-1 123596
17 Protein Kinase Inhibitors Phase 2
18
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
19
Emodepside Investigational, Vet_approved Phase 1 155030-63-0
20 Pharmaceutical Solutions Phase 1
21
Polidocanol Approved 9002-92-0
22
Piperazine Approved, Vet_approved 110-85-0 4837
23
Mebendazole Approved, Vet_approved 31431-39-7 4030
24
Sodium citrate Approved, Investigational 68-04-2
25
Permethrin Approved, Investigational 52645-53-1 40326
26
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
27 Anesthetics
28 Sclerosing Solutions
29 Piperazine citrate
30 Citrate
31 DMP 777 157341-41-8
32 Liver Extracts
33 Insect Repellents

Interventional clinical trials:

(show top 50) (show all 58)
# Name Status NCT ID Phase Drugs
1 Impact of Albendazole -Ivermectin Combination Treatment on Wuchereria Bancrofti Infection and Transmission in Mali Completed NCT02784743 Phase 4 ''albendazole'' and ''ivermectin''
2 Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection: Double Blind Randomised Clinical Trial (RCT) to Study the Efficacy of Different Co-administration and Sequential Administration Completed NCT02005653 Phase 4 Diethylcarbamazine;Albendazole;Doxycycline
3 Comparison Between the Post-Treatment Reactions After Single-dose Ivermectin or DEC in Subjects With Loa Loa Infection Completed NCT01593722 Phase 4 Diethylcarbamazine;Ivermectin
4 Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations Recruiting NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
5 Safety of the Co-administration of Azithromycin, Albendazole and Ivermectin Versus Standard Treatment Regimens During Mass Drug Administration (MDA) in Ethiopia: a Cluster-randomized Trial Not yet recruiting NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
6 AZIVAL 2: A Double-blind Cluster-randomized Placebo-controlled Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults With Azithromycin, Ivermectin and Albendazole Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
7 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study Withdrawn NCT02734186 Phase 4 Praziquantel
8 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed NCT02509481 Phase 2, Phase 3 Ivermectin;Albendazole
9 A Cluster Randomised Trial of the Safety of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
10 Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis Completed NCT03238131 Phase 3 Ivermectin;Albendazole
11 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) Recruiting NCT03014167 Phase 3 Albendazole
12 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929134 Phase 3 Doxycycline;Placebo
13 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929121 Phase 3 Doxycycline;Placebo
14 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02927496 Phase 3 Doxycycline;Placebo
15 Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa Completed NCT01975441 Phase 2 Diethylcarbamazine;Albendazole;Ivermectin
16 Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00511004 Phase 2 Albendazole;Diethylcarbamazine
17 A Pharmacokinetic and Pharmacodynamic Evaluation of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03664063 Phase 2 Azithromycin;Albendazole;Ivermectin;Diethylcarbamazine
18 Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study Completed NCT00339417 Phase 2 Albendazole;Ivermectin
19 Effect of Albendazole Dose and Interval on Wuchereria Bancrofti Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00375583 Phase 2 DEC/Albendazole
20 Treatment of Mansonella Perstans Infection in an Area Coendemic for Lymphatic Filariasis: A Pilot Study of the Effects of Doxycycline Completed NCT00340691 Phase 2 Doxycycline
21 Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study (IVERMAL) Completed NCT02511353 Phase 2 ivermectin;placebo;dihydroartemisinin-piperaquine
22 A Randomized, Placebo-controlled, Double-Blind Pilot Study of Single-Dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa Loa Infection Completed NCT01111305 Phase 2 Reslizumab;Diethylcarbamazine
23 A Double-Blinded, Randomized, Placebo-Controlled Dose Escalation Study to Examine the Microfilaricidal Kinetics and Safety of Imatinib for the Treatment of Loa Loa (A Pilot Study) Recruiting NCT02644525 Phase 2 Imatinib Mesylate;Placebo
24 Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis Recruiting NCT04188301 Phase 2 IVM w/ ALB;Single dose of IDA;Three daily doses of IDA
25 A Phase 1, Single-Blind, Randomized, Placebo Controlled, Parallel-Group, Multiple-Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT03383614 Phase 1 LSF emodepside (BAY 44-4400) oral solution (1mg/mL)
26 A Phase 1, Blinded, Randomized, Placebo Controlled, Parallel-Group, Single-Dose, Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT02661178 Phase 1 emodepside (BAY 44-4400);placebo
27 Phase1,Randomized,Open-Label,Parallel-Group,Relative Bioavailability Study to Investigate PK,Including Food Effect,Safety and Tolerability of Single Doses of New Immediate Release Tablet Formulations of Emodepside (BAY 44-4400),Compared to Oral Solution,in Healthy Male Subjects Completed NCT03383523 Phase 1 Emodepside (BAY 44-4400)
28 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Dose Treatment With Diethylcarbamazine, Albendazole and Ivermectin in Humans With and Without Wuchereria Bancrofti Infection in Côte d'Ivoire Completed NCT02845713 Phase 1 Ivermectin, Diethylcarbamazine Albendazole (IDA)
29 Lord´s Procedure Versus Sclerotherapy for Testicular Hydrocele; a Randomized Controlled Study. Unknown status NCT02082613
30 Exhaled NO Testing in Filariasis Completed NCT01628497
31 Research for Elimination of Lymphatic Filariasis (ICIDR) Completed NCT00406627
32 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India Completed NCT01629771
33 Research for Elimination of Human Filariasis Completed NCT00145223
34 A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali Completed NCT01586169 triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
35 Studies on the Interaction Between HIV Infection, Lymphatic Filariasis and Diethylcarbamazine Completed NCT00295698 Diethylcarbamazine
36 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis Completed NCT02899936 3 drug dose - IDA;2 drug dose - DA
37 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole and diethylcarbamazine
38 Coinfection With Plasmodium Falciparum and Wuchereria Bancrofti: Clinical, Epidemiologic and Immunologic Implications Completed NCT00471666
39 Evaluation of Antibacterial Soap for Treatment of Lymphedema and Elephantiasis in an Area Endemic for Lymphatic Filariasis Completed NCT00139100 antimicrobial agent in soap
40 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
41 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Liberia Completed NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
42 Changes in HIV Viral Load in Patients Undergoing Treatment for Filarial Infection Completed NCT00344279
43 Gaps in Helminth Control: Safety and Efficacy of Drug Combinations Against Triple Infections Completed NCT01050517 albendazole + ivermectin + praziquantel;albendazole + ivermectin + (1 week later) praziquantel
44 Regulation of Innate and Adaptive Immune Responses in Individuals Infected Concurrently With Malarial and Filarial Parasites Completed NCT00341666
45 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji Completed NCT03177993 3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA
46 Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire] Completed NCT02974049 Albendazole;Ivermectin;Diethylcarbamazine
47 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis: Monitoring Efficacy of Ongoing Treatment Programs in Papua New Guinea Completed NCT03268252
48 Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas Completed NCT03131401
49 Community-Directed Treatment in the Control of Soil-Transmitted Helminths Among Children Aged 12-59 Months in Mazabuka District of Zambia Completed NCT00349323
50 Study of Patients With Known or Suspected Infection With Strongyloides Stercoralis Completed NCT00001245

Search NIH Clinical Center for Filariasis

Cochrane evidence based reviews: filariasis

Genetic Tests for Filariasis

Anatomical Context for Filariasis

MalaCards organs/tissues related to Filariasis:

40
Testes, T Cells, Breast, Skin, Lung, Liver, B Cells

Publications for Filariasis

Articles related to Filariasis:

(show top 50) (show all 6318)
# Title Authors PMID Year
1
Protective immunity in human filariasis: a role for parasite-specific IgA responses. 54 61
18588480 2008
2
Chitotriosidase deficiency is not associated with human hookworm infection in a Papua New Guinean population. 54 61
17765019 2007
3
IgE memory: persistence of antigen-specific IgE responses years after treatment of human filarial infections. 54 61
16630955 2006
4
Interleukin-10 (IL-10) counterregulates IL-4-dependent effector mechanisms in Murine Filariasis. 54 61
15501755 2004
5
Polymorphisms of innate immunity genes and susceptibility to lymphatic filariasis. 54 61
14551607 2003
6
A four year follow up study of filaria specific IgE response in individuals with hydrocele. 54 61
11247197 2000
7
IL-5 is essential for vaccine-induced protection and for resolution of primary infection in murine filariasis. 54 61
11138639 2000
8
Antigen-stimulated IL-4, IL-13 and IFN-gamma production by human T cells at a single-cell level. 54 61
9808184 1998
9
Differential decline in filaria-specific IgG1, IgG4, and IgE antibodies in Brugia malayi-infected patients after diethylcarbamazine chemotherapy. 54 61
7594718 1995
10
Differential antibody isotype reactivity to specific antigens in human lymphatic filariasis: gp15/400 preferentially induces immunoglobulin E (IgE), IgG4, and IgG2. 54 61
7558279 1995
11
Differential expression of IgE and IgG4 specific antibody responses in asymptomatic and chronic human filariasis. 54 61
8473742 1993
12
Cytokine regulation of antigen-driven immunoglobulin production in filarial parasite infections in humans. 54 61
2112154 1990
13
Advances in Vaccine Development for Human Lymphatic Filariasis. 61
31864894 2020
14
Massive microfilaremia in a dog subclinically infected with Acanthocheilonema dracunculoides. 61
32036036 2020
15
Activation of mosquito immunity blocks the development of transmission-stage filarial nematodes. 61
32015105 2020
16
Ivermectin concentration in breastmilk of a woman with Strongyloides stercoralis and human T-lymphotropic virus-I co-infection. 61
31678122 2020
17
The genome of Setaria digitata, a cattle nematode closely related to human filarial parasites. 61
32022853 2020
18
The rise or fall of neglected tropical diseases in East Asia Pacific. 61
31550453 2020
19
Schistosomiasis, strongyloidiasis and Chagas disease: the leading imported neglected tropical diseases in Italy. 61
31840757 2020
20
Filariasis with Squamous Cell Carcinoma: A Hidden Surprise. 61
32002388 2020
21
Genital filariasis presenting as a vaginal wall cystic lesion. 61
31768314 2020
22
Cutaneous Filariasis in Free-Ranging Rothschild's Giraffes (Giraffa camelopardalis rothschildi) in Uganda. 61
31532733 2020
23
Loa loa filariasis in a tropical savanna area: report of one case in Ouagadougou. 61
31975376 2020
24
A review on the druggability of a thiol-based enzymatic antioxidant thioredoxin reductase for treating filariasis and other parasitic infections. 61
31521661 2020
25
Molecular xenomonitoring as a post-MDA surveillance tool for global programme to eliminate lymphatic filariasis: Field validation in an evaluation unit in India. 61
31978060 2020
26
Frequency and Clinical Significance of Localized Adverse Events following Mass Drug Administration for Lymphatic Filariasis in an Endemic Area in South India. 61
31769393 2020
27
Brugia malayi galectin 2 is a tandem-repeat type galectin capable of binding mammalian polysaccharides. 61
31738955 2020
28
In vivo efficacy of the boron-pleuromutilin AN11251 against Wolbachia of the rodent filarial nematode Litomosoides sigmodontis. 61
31986143 2020
29
Isolated Epitrochlear Filarial Lymphadenopathy: Cytomorphological Diagnosis of an Unusual Presentation. 61
29630086 2020
30
Design and Analysis of Elimination Surveys for Neglected Tropical Diseases. 61
31930383 2020
31
Antifilarial effect of nanocomposite of silver nanoparticles with nitazoxanide against the microfilariae of Setaria cervi-infected albino rats. 61
32002575 2020
32
Integrated Cross-Sectional Multiplex Serosurveillance of IgG Antibody Responses to Parasitic Diseases and Vaccines in Coastal Kenya. 61
31769388 2020
33
High Circulation of Malaria and Low Prevalence of Bacteremia in Febrile and Afebrile Children in Northeastern Gabon. 61
31769404 2020
34
Safety of high-dose ivermectin: a systematic review and meta-analysis. 61
31960060 2020
35
Lymphedema in three previously Wuchereria bancrofti-endemic health districts in Mali after cessation of mass drug administration. 61
31941448 2020
36
From parasitic disease control to global health: New orientation of the National Institute of Parasitic Diseases, China CDC. 61
31614120 2020
37
Testing a method of sampling for entomological determination of transmission of Wuchereria bancrofti to inform lymphatic filariasis treatment strategy in urban settings. 61
31973747 2020
38
Macrofilaricidal Benzimidazole-Benzoxaborole Hybrids as an Approach to the Treatment of River Blindness: Part 1. Amide Linked Analogs. 61
31876154 2020
39
Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study. 61
31948767 2020
40
Antibody response to Schistosoma haematobium and other helminth species in malaria-exposed populations from Burkina Faso. 61
32007449 2020
41
Role of Bone Marrow Examination in the Evaluation of Infections: Clinico-Hematological Analysis in a Tertiary Care Centre. 61
31522489 2020
42
Elimination or Resurgence: Modelling Lymphatic Filariasis After Reaching the 1% Microfilaremia Prevalence Threshold. 61
31853554 2019
43
An insight into the discovery of potent antifilarial leads against lymphatic filariasis. 61
31800381 2019
44
Solid lipid nanoparticle-based dissolving microneedles: A promising intradermal lymph targeting drug delivery system with potential for enhanced treatment of lymphatic filariasis. 61
31655132 2019
45
Canine Brugia malayi microfilarial excretory/secretory protein-based antibody assay for the diagnosis of brugian filariasis in dogs. 61
31749523 2019
46
Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics. 61
31796568 2019
47
An Expanded Transmission Assessment Survey to Confirm the Interruption of Lymphatic Filariasis Transmission in Wallis and Futuna. 61
31595868 2019
48
Surgical Treatment of Advanced Lymphatic Filariasis of Lower Extremity Combining Vascularized Lymph Node Transfer and Excisional Procedures. 61
31038386 2019
49
The consequences of Brugia malayi infection on the flight and energy resources of Aedes aegypti mosquitoes. 61
31804546 2019
50
De novo Assembly of the Brugia malayi Genome Using Long Reads from a Single MinION Flowcell. 61
31863009 2019

Variations for Filariasis

Expression for Filariasis

Search GEO for disease gene expression data for Filariasis.

Pathways for Filariasis

Pathways related to Filariasis according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.09 TNF TLR9 TLR6 TLR4 TLR2 TLR1
2
Show member pathways
13.73 TNF TLR4 IL6 IL5 IL2 IL10
3
Show member pathways
13.58 TNF IL6 IL5 IL2 IL10 IFNG
4
Show member pathways
13.48 TNF TLR9 TLR6 TLR4 TLR2 TLR1
5
Show member pathways
13.43 TNF IL6 IL5 IL2 IL10 IGHE
6
Show member pathways
13.35 TNF IL6 IL5 IL2 IL10 FLT4
7
Show member pathways
13.3 TNF TLR9 TLR6 TLR4 TLR2 TLR1
8
Show member pathways
13.19 TNF TLR9 TLR6 TLR4 TLR2 TLR1
9
Show member pathways
13.04 TNF TLR4 TLR2 IL6 IL2 FLT4
10
Show member pathways
12.96 TNF IL6 IL5 IL2 IL10 IFNG
11
Show member pathways
12.92 TNF TLR9 TLR4 TLR2 IL6 IL2
12 12.88 TNF TLR9 TLR2 IL6 IFNG CCL5
13
Show member pathways
12.81 TNF TLR4 IL6 IFNG CCL5
14
Show member pathways
12.8 TNF TLR9 TLR6 TLR4 TLR2 TLR1
15
Show member pathways
12.72 TNF TLR4 TLR2 IL6 IL5 IL2
16
Show member pathways
12.7 TNF TLR9 TLR6 TLR4 TLR2 TLR1
17
Show member pathways
12.69 TNF IL2 IL10 IGHE IFNG
18
Show member pathways
12.66 TNF IL6 IL2 IL10 IFNG
19
Show member pathways
12.56 TNF TLR9 TLR4 TLR2 IL6 IL5
20
Show member pathways
12.53 TLR9 TLR6 TLR4 TLR2 TLR1 FLT4
21
Show member pathways
12.46 IL6 IL5 IL2 IL10 IFNG
22
Show member pathways
12.46 TNF IL6 IL2 IFNG CCL5 ALB
23
Show member pathways
12.44 TNF TLR2 IL6 IL5 IFNG
24
Show member pathways
12.44 TNF IL6 IL2 IL10 CCL5
25
Show member pathways
12.39 TNF TLR9 TLR6 TLR4 TLR2 TLR1
26
Show member pathways
12.38 TNF IL6 IL5 IL2 IL10 IFNG
27
Show member pathways
12.37 TNF TLR4 TLR2 IL10 IFNG
28
Show member pathways
12.33 TNF TLR9 IL6 IL2 IL10
29 12.29 TNF TLR4 IL6 CCL5
30 12.25 TNF TLR9 TLR6 TLR4 TLR2 TLR1
31
Show member pathways
12.22 TNF TLR9 TLR6 TLR4 TLR2 TLR1
32 12.21 TNF TLR9 TLR6 TLR2 TLR1 PDCD1LG2
33 12.15 TNF IL6 IL5 IL2 IL10 IFNG
34 12.14 TNF TLR4 IL6 IL2 IL10
35
Show member pathways
12.14 TNF TLR6 TLR4 TLR2 TLR1 IL6
36 12.13 TNF TLR4 IL6 IL2 IFNG
37
Show member pathways
12.11 TLR9 TLR6 TLR4 TLR2 TLR1 IL5
38 12.08 TNF IL6 IL10 IGHE
39 12.08 TNF TLR4 TLR2 IL6 IL10 IFNG
40 12.06 TNF TLR9 TLR6 TLR4 TLR2 TLR1
41 11.97 IL6 IL2 IL10 IFNG
42 11.97 TNF TLR4 TLR2 IL6 IFNG CTLA4
43 11.96 TLR9 TLR6 TLR4 TLR2 TLR1
44 11.92 IL6 IL5 IL2 IFNG
45 11.92 TNF IL5 IL2 IL10 IFNG
46
Show member pathways
11.9 TNF IL5 IL2 IFNG CTLA4
47 11.89 TNF TLR9 IL6 IL2 IL10 IFNG
48 11.88 TNF TLR4 IL6 IL10
49 11.86 TNF IL6 IL2 IL10 IFNG CCL5
50 11.82 TLR4 IL6 IFNG

GO Terms for Filariasis

Cellular components related to Filariasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.67 TNF TLR6 TLR2 TLR1
2 external side of plasma membrane GO:0009897 9.65 TNF TLR4 PDCD1LG2 IGHE CTLA4
3 extracellular space GO:0005615 9.65 TNF LGALS3BP IL6 IL5 IL2 IL10
4 phagocytic vesicle membrane GO:0030670 9.5 TLR6 TLR2 TLR1
5 extracellular region GO:0005576 9.47 TNF TLR9 PDCD1LG2 LGALS3BP IL6 IL5
6 Toll-like receptor 1-Toll-like receptor 2 protein complex GO:0035354 9.16 TLR2 TLR1

Biological processes related to Filariasis according to GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.36 TLR9 TLR6 TLR4 TLR2 TLR1 PDCD1LG2
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.31 TNF TLR9 TLR4 TLR2 IL6 IL2
3 innate immune response GO:0045087 10.2 TLR9 TLR6 TLR4 TLR2 TLR1 IGHE
4 positive regulation of gene expression GO:0010628 10.15 TNF TLR9 TLR6 TLR4 TLR2 IL6
5 immune system process GO:0002376 10.11 TLR9 TLR6 TLR4 TLR2 TLR1 PDCD1LG2
6 defense response to bacterium GO:0042742 10.08 TNF TLR9 TLR6 TLR4 IL10 IGHE
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.06 TNF TLR4 FLT4 CCL5
8 cellular response to lipopolysaccharide GO:0071222 10.06 TNF TLR4 PDCD1LG2 IL6 IL10
9 positive regulation of protein phosphorylation GO:0001934 10.05 TNF IL2 IFNG FLT4
10 cytokine-mediated signaling pathway GO:0019221 10.05 TNF IL6 IL5 IL2 IL10 IGHE
11 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.04 TNF TLR9 TLR6 TLR4
12 positive regulation of DNA-binding transcription factor activity GO:0051091 10.01 TNF IL6 IL5 IL10
13 positive regulation of JNK cascade GO:0046330 9.98 TNF TLR9 TLR4 FLT4
14 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.97 TNF TLR9 TLR6 TLR4 TLR2 IL6
15 positive regulation of T cell proliferation GO:0042102 9.96 PDCD1LG2 IL6 IL2 CCL5
16 positive regulation of inflammatory response GO:0050729 9.96 TNF TLR9 TLR4 TLR2 IL2
17 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.95 TNF TLR9 TLR4 TLR2
18 regulation of insulin secretion GO:0050796 9.93 TNF IFNG CCL5
19 response to glucocorticoid GO:0051384 9.93 TNF IL6 IL10
20 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.93 TNF TLR9 TLR4
21 positive regulation of smooth muscle cell proliferation GO:0048661 9.92 TNF IL6 CCL5
22 humoral immune response GO:0006959 9.92 TNF IL6 IFNG
23 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.92 TNF IL6 IL2 IFNG CCL5
24 positive regulation of tumor necrosis factor production GO:0032760 9.91 TLR9 TLR4 TLR2
25 negative regulation of T cell proliferation GO:0042130 9.91 PDCD1LG2 IL10 CTLA4
26 positive regulation of interferon-gamma production GO:0032729 9.91 TNF TLR4 IL2
27 positive regulation of nitric oxide biosynthetic process GO:0045429 9.91 TNF TLR6 TLR4 IFNG
28 positive regulation of JUN kinase activity GO:0043507 9.9 TNF TLR9 TLR6
29 positive regulation of interleukin-6 secretion GO:2000778 9.9 TNF TLR4 TLR2
30 negative regulation of interferon-gamma production GO:0032689 9.89 TLR4 PDCD1LG2 IL10
31 positive regulation of B cell proliferation GO:0030890 9.89 TLR9 TLR4 IL5 IL2
32 positive regulation of interferon-beta production GO:0032728 9.88 TLR9 TLR4 TLR2
33 negative regulation of interleukin-6 production GO:0032715 9.88 TNF TLR9 TLR4 IL10
34 lipopolysaccharide-mediated signaling pathway GO:0031663 9.88 TNF TLR4 TLR2 CCL5
35 positive regulation of interleukin-6 production GO:0032755 9.88 TNF TLR9 TLR4 TLR2 IL6
36 microglial cell activation GO:0001774 9.87 TNF TLR6 TLR2 IFNG
37 positive regulation of interleukin-10 production GO:0032733 9.86 TLR9 TLR4 TLR2
38 positive regulation of tumor necrosis factor biosynthetic process GO:0042535 9.85 TLR4 TLR1 IFNG
39 positive regulation of macrophage activation GO:0043032 9.85 TLR6 TLR4 IL10
40 positive regulation of interleukin-8 secretion GO:2000484 9.85 TLR4 TLR2 TLR1
41 positive regulation of interleukin-8 production GO:0032757 9.85 TNF TLR9 TLR4 TLR2
42 regulation of regulatory T cell differentiation GO:0045589 9.84 IL2 IFNG CTLA4
43 positive regulation of interleukin-12 production GO:0032735 9.84 TLR9 TLR4 TLR2 IFNG
44 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.83 TNF TLR6 TLR1
45 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.82 TNF TLR9 TLR4
46 positive regulation of immunoglobulin secretion GO:0051024 9.82 IL6 IL5 IL2
47 I-kappaB phosphorylation GO:0007252 9.81 TLR9 TLR4 TLR2
48 response to molecule of bacterial origin GO:0002237 9.81 TLR9 TLR2 IL10
49 cell activation GO:0001775 9.8 TLR6 TLR2 TLR1
50 positive regulation of MHC class II biosynthetic process GO:0045348 9.8 TLR4 IL10 IFNG

Molecular functions related to Filariasis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.36 TNF TLR9 TLR6 TLR4 TLR2 TLR1
2 signaling receptor activity GO:0038023 9.76 TLR6 TLR4 TLR2 TLR1
3 identical protein binding GO:0042802 9.76 TNF TLR6 TLR4 TLR2 TLR1 FOXC2
4 transmembrane signaling receptor activity GO:0004888 9.73 TLR9 TLR6 TLR4 TLR1
5 growth factor activity GO:0008083 9.67 IL6 IL5 IL2 IL10
6 amyloid-beta binding GO:0001540 9.65 TLR6 TLR4 TLR2
7 signaling pattern recognition receptor activity GO:0008329 9.49 TLR9 TLR2
8 lipopolysaccharide receptor activity GO:0001875 9.32 TLR4 TLR2
9 Toll-like receptor 2 binding GO:0035663 9.26 TLR6 TLR1
10 cytokine activity GO:0005125 9.17 TNF IL6 IL5 IL2 IL10 IFNG
11 lipopeptide binding GO:0071723 9.13 TLR6 TLR2 TLR1

Sources for Filariasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....